LIVECAST Markets Briefs Calendar

Research

News Search AI Market Assistant Charts & News Instrument directory Macro Politics Prediction Markets News Archive

LIVECAST Markets

☀◐Theme

Menu

Home LIVECAST Markets Briefs Calendar News Search AI Market Assistant Charts & News Instrument directory Macro Politics Prediction Markets News Archive Account

Live News EQUITY FLASH L impact Oct 01, 2026, 01:06 PM UTC

Semtech Is Maintained at Outperform by Oppenheimer

Ratings actions

SquawkNews Desk

Use this page

Share or save this market-moving headline as a permanent SquawkNews URL. The live feed continues at /news.

Open live news feed Browse news archive Browse news categories Search related coverage

Related tickers

SMTC

Related stories

Telos Corp. Wins 3-Year $13.5M Air Force Contract Telos Corporation secured a three-year, $13.5 million contract from the 16th Air Force to supply Xacta license maintenance, training, and cyber services for AF ISR systems within t M impact | EQUITY | Oct 05, 2026, 07:01 PM UTC Telos wins $13.5 mln 16th Air Force cyber support contract Telos received a three-year, $13.5 million contract from the 16th Air Force to support cyber operations for the Air Force Intelligence Community. The work includes license maintena M impact | EQUITY | Oct 05, 2026, 07:01 PM UTC US session market picture: S&P 500 +0.7%, Nasdaq 100 +0.8%; EUR/USD -0.35%, WTI -2.38%, WBD leads volume US session market picture. US index futures: S and P futures is up 0.7 percent, Nasdaq futures is up 0.8 percent, Dow futures is up 0.24 percent and Russell futures is up 0.61 perc M impact | EQUITY | Oct 05, 2026, 07:00 PM UTC The United States Stock Market Index (US500) Hit 7-week High US500 increased to 7783.00 Index Points, the highest since August 2026. Over the past 4 weeks, United States Stock Market Index (US500) gained 1.41%, and in the last 12 months, it L impact | EQUITY | Oct 05, 2026, 06:57 PM UTC Italfarmaco and VeriSIM Life partner on novel therapeutics for rare diseases Italfarmaco and VeriSIM Life announced a strategic collaboration to discover and develop novel HDAC-targeted therapeutic assets for neuromuscular, fibrotic, and rare diseases. The M impact | EQUITY | Oct 05, 2026, 06:51 PM UTC Genmab, AbbVie drug combo shows 51% lower risk of progression in lymphoma trial The EPCORE DLBCL-2 trial showed that epcoritamab combined with R-CHOP reduced the risk of disease progression or death by 51% compared to R-CHOP alone in newly diagnosed diffuse la M impact | EQUITY | Oct 05, 2026, 06:50 PM UTC

SQUAWK/NEWS

Independent financial newsroom. Editorial expertise and proprietary AI. Paid LiveCast brings live headlines, chart context and priority audio to your trading day. Free research tools remain available.

LiveCast passes from $15 · Institutional API access.

Start LiveCast

News & Research

Open LiveCast
Session Briefs
Macro
Politics
Prediction Markets
News Archive

Markets & Tools

Charts & News
Markets Overview
US Stocks
Market Movers
Economic Calendar
Policy Calendar
AI Market Assistant
News Search
Instrument Directory

Guides

Charts & News Guide
How LiveCast Works
What Is an Audio Squawk?
Why News Moves Markets
News for Traders
How to Trade the News

Plans & API

Plans & Pricing
Institutional API
RSS Feed

Company

About
Why SquawkNews
Newsroom
Editorial Standards
Corrections
Contact us

© 2026 SquawkNews

Privacy Policy Terms of Use

SquawkNews publishes market information and context. It does not provide investment advice or trade recommendations.